Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
暂无分享,去创建一个
Piero Musiani | Federica Cavallo | Annalisa Astolfi | Manuela Iezzi | Arianna Palladini | Patrizia Nanni | Guido Forni | Pier-Luigi Lollini | P. Musiani | P. Lollini | G. Forni | M. Iezzi | S. Ferrini | P. Nanni | C. De Giovanni | A. Astolfi | F. Cavallo | A. Palladini | G. Nicoletti | S. Croci | L. Landuzzi | Giordano Nicoletti | Carla De Giovanni | Lorena Landuzzi | Silvano Ferrini | Stefania Croci
[1] Piero Musiani,et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. , 2004, The Journal of clinical investigation.
[2] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[3] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[4] Richard Simon,et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[5] R. Cardiff,et al. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. , 2003, Cancer research.
[6] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] Piero Musiani,et al. Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine , 2004, Cancer Research.
[8] Gregor Mikuz,et al. Ep-CAM overexpression in breast cancer as a predictor of survival , 2000, The Lancet.
[9] P. Leder,et al. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. , 1994, Oncogene.
[10] Makoto Katsumata,et al. Prevention of breast tumour development in vivo by downregulation of the p185neureceptor , 1995, Nature Medicine.
[11] O. Finn,et al. Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.
[12] Allison Jones,et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells , 2003, Oncogene.
[13] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[14] S. Morrison,et al. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. , 2003, Vaccine.
[15] S. Ménard,et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination , 2001, Gene Therapy.
[16] D. Hilton,et al. SOCS: physiological suppressors of cytokine signaling. , 2000, Journal of cell science.
[17] T. Speed,et al. Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.
[18] G H Smith,et al. Mammary epithelial stem cells , 2001, Microscopy research and technique.
[19] P. Musiani,et al. Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN-γ and B Cell Dependent1 , 2004, The Journal of Immunology.
[20] Joseph Geradts,et al. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. , 2002, The American journal of pathology.
[21] A. Amici,et al. Genetic immunization against neu /erbB2 transgenic breast cancer , 1998, Cancer Immunology, Immunotherapy.
[22] William C Reinhold,et al. MatchMiner: a tool for batch navigation among gene and gene product identifiers , 2003, Genome Biology.
[23] M. Colombo,et al. IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1 , 2003, The Journal of Immunology.
[24] Piero Musiani,et al. Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.
[25] P. Musiani,et al. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER‐2/neu transgenic mice , 1998, International journal of cancer.
[26] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[27] Alan Ashworth,et al. Stem cells and breast cancer: A field in transit , 2003, Nature Reviews Cancer.
[28] P. Rouleau,et al. Proinflammatory Activities of S100: Proteins S100A8, S100A9, and S100A8/A9 Induce Neutrophil Chemotaxis and Adhesion 1 , 2003, The Journal of Immunology.
[29] J. Visvader,et al. The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Ménard,et al. p185neu protein is required for tumor and anchorage‐independent growth, not for cell proliferation of transgenic mammary carcinoma , 2000, International journal of cancer.
[31] A I Saeed,et al. TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.
[32] A. Chinnaiyan,et al. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. , 2003, Cancer research.
[33] P. Lollini,et al. Cancer immunoprevention: tracking down persistent tumor antigens. , 2003, Trends in immunology.
[34] J. Mesirov,et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[35] P. Basset,et al. Definition of the tumor protein D52 (TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52). , 1996, Genomics.
[36] A. Sckell,et al. Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer , 1999, International journal of cancer.
[37] P. Musiani,et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[38] L. Esserman,et al. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice , 1999, Cancer Immunology, Immunotherapy.
[39] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[40] P. Glazer,et al. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. , 1998, Cancer research.
[41] Gould Mn,et al. Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas. , 1995 .
[42] R. Spang,et al. Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[43] P. Triozzi,et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. , 2000, Cancer research.
[44] Piero Musiani,et al. Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.
[45] M. Piechocki,et al. Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-21 , 2001, The Journal of Immunology.